Company Profile

BioTime Inc
Profile last edited on: 9/11/19      CAGE: 5ZH96      UEI: JB7RMLG8U699

Business Identifier: Regenerative medicine for aging-related diseases and cancer
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1010 Atlantic Avenue Unit 102
Alameda, CA 94501
   (510) 521-3390
Location: Single
Congr. District: 13
County: Alameda

Public Profile

in November 2018, BioTime Inc. re-acquired an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 16.2%. BioTime Inc, is a biotechnology company focused on biomedical research and product development in the field of regenerative medicine: specifically, new therapeutics for age-related degenerative disease. Based on stem cell technology, BioTime's regenerative medicine therapies are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Focused on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells which provide a means to manufacture every type of cell in the human body, BioTime’s HyStem hydrogels represent a core enabling technology for regenerative medicine and cellular delivery and are used by researchers worldwide for tissue engineering, 2D and 3D cell culture, and disease models. HyStem is a biomaterial that mimics the human extracellular matrix, a network of molecules surrounding cells in organs and tissues which is essential to cellular function. HyStem hydrogels may have other applications when combined with cell types BioTime scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's subsidiaries include various regenerative medicine companies developing novel tr

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  The Late Paul E Segall -- co-founder and CEO

  Michael D West -- Founder and Chief Executive Officer

  Isaac Erickson

  Walter Funk -- Vice-President of Stem Cell Technology

  Peter Garcia -- Chief Financial Officer

  Jeffrey D Janus -- Vice President of Sales & Marketing

  Igor Nasonkin

  Robert W Peabody -- Senior Vice President; Chief Operating Officer; Chief Financial Officer

  Judith Segall -- Co-Founder; Vice President of Administration; Corporate Secretary

  Steven A Seinberg

  Hal Sternberg -- Co-Founder; Vice President of Research

  Lesley Stolz -- Executive Vice President of Corporate Development

  William P Tew -- Chief Commercial Officer